Management of chronic obstructive pulmonary disease: An emphasis on recently approved medications and products in the pipeline

Formulary

Volumn 46, Issue 9, 2011, Pages 374-393

  Hudd, Timothy R ^a   Zaiken, Kathy ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ARFORMOTEROL; ATROVENT SOLUTION; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BROVANA SOLUTION; BUDESONIDE; CARMOTEROL; COMBIVENT MDI; CORTICOSTEROID; DUONEB SOLUTION; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; GLYCOPYRRONIUM BROMIDE; GSK 573719; GSK 961081; INDACATEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LAS 100977; LAS 40464; LEVALBUTEROL; MOMETASONE FUROATE; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PERFOROMIST SOLUTION; PIRBUTEROL; PIRBUTEROL ACETATE; PLACEBO; PNEUMOCOCCUS VACCINE; PT 003; QMF 149; QVA149; ROFLUMILAST; SALBUTAMOL SULFATE; SALMETEROL XINAFOATE; SYMBICORT HFA; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; VILANTEROL; XOPENEX SOLUTION;

ANXIETY; AREA UNDER THE CURVE; BITTER TASTE; BLURRED VISION; BRONCHODILATATION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COUGHING; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EMPHYSEMA; EXERCISE TOLERANCE; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEALTH CARE COST; HEALTH STATUS; HOSPITALIZATION; HUMAN; INSOMNIA; METERED DOSE INHALER; NAUSEA; NEBULIZATION; PNEUMOCOCCAL INFECTION; POLLUTANT; POWDER INHALER; PSYCHOLOGICAL WELL BEING; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING CESSATION; SORE THROAT; SPIROMETRY; STEADY STATE; TACHYCARDIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; WEIGHT REDUCTION; XEROSTOMIA;

EID: 81155123543     PISSN: 1082801X     EISSN: 19381166     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Global strategy for the diagnosis, management, and prevention of COPD. Updated 2010. Available at: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed August 11, 2011.
2. Williams DM, Bourdet SV. Chronic obstructive pulmonary disease. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2011:471-495.
3. American Thoracic Society/European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD. Version 1.2. New York: American Thoracic Society; 2004. Updated September 8, 2005. Available at: http://www.thoracic.org/clinical/copd-guidelines/.Accessed August 11, 2011.
4. American Lung Association: Chronic obstructive pulmonary disease (COPD) fact sheet. February 2011. Available at: http:// www.lungusa.org/lung-disease/copd/resources/facts-flgures/COPD-Fact-Sheet.html. Accessed August 11, 2011.
5. Gist YJ, Hetzel LI; US Census Bureau. We the people: aging in the United States. Census 2000 special reports. Washington, DC: US Census Bureau, 2004.
6. Brown DW, Croft JF, Greenlund KJ, Giles WH. Deaths from chronic obstructive pulmonary disease-United States,20002005. Surveillance summaries. MMWR. 2008;57:1229-1232.
7. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. Surveillance summaries. MMWR. 2002;51:1-16.
8. Seemungal TAR, Hurst JR, Wedzicha JA. Exacerbation rate, health status, and mortality in COPD-a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 2009;4:203-223.
9. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Expert Panel Report 3, Publication No. 08-5846. Bethesda, MD: U.S. Department of Health and Human Services; Oct 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/. Accessed August 11, 2011.
10. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269-280.
11. Cazzola M, Molimard M. The scientiflc rational for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23:257-267.
12. Red Book Online, Thomson Reuters, 2011.
13. Uniphyl [package insert]. Stamford, CT: Purdue Pharmaceutical Products; 2004.
14. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179-191.
15. Berger WE. Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma. Ann Allergy Asthma Immunol. 2003;90:583-591.
16. Datta D, Vitale A, Lahiri B, ZuWallack R. An evaluation of nebulized levalbuterol in stable COPD. Chest. 2003;124:844-849.
17. Hulisz D. How does levalbuterol (Xopenex) compare with albuterol? Medscape Pharmacists. 2010. Updated March 30, 2010. Available at: www.medscape.com/pharmacists. Accessed August 11, 2011.
18. Brovana [package insert]. Marlborough, MA: Sunovion Pharmaceuticals; 2011.
19. Foradil Aerolizer [package insert]. Basel, Switzerland: Novartis Pharmaceuticals; 2010.
20. Mahler DA, Donohue JF, Barbee RA, et al. Efflcacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957-965.
21. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1087-1092.
22. Van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 1996;9:1684-1688.
23. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26.
24. Tashkin DP, Fabbri LM. Long-acting betaagonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149.
25. Atrovent Inhalation Aerosol [package insert]. Ridgefleld, CT: Boehringer Ingelheim Pharmaceuticals;1998.
26. Barnes PJ. The pharmacological properties of tiotropium. Chest. 2000;117:63S-66S.
27. Verkindre C, Fukuchi Y, Flemale A, et al. Sustained 24-hour efflcacy of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010;104:1482-1489.
28. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
29. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404.
30. Lee TA, Pickard S, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149:380-390.
31. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439-1450.
32. FDA. Follow-Up to the October 2008 updated early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). Post market drug safety information for patients and providers. January 14, 2010. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm197429.htm. Accessed August 11, 2011.
33. Tashkin DP, Celli B, Senn S, et al; for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
34. Calverley PMA, Anderson JA, Celli B, et al; for the TORCH investigators. Salmeterol and fiuticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.
35. CDC. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR. 2010;59:1102-1106. Available at: http://www.cdc.gov/mmwr/pdf/wk/mm5934.pdf. Accessed August 11, 2011.
36. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-338.
37. Cazzola M, MacNee W, Martinez FJ, et al; for the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416-468.
38. Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health-Syst Pharm. 2011;68:1221-1232.
39. Daliresp [package insert]. St. Louis, MO: Forest Laboratories; February 2011.
40. Giembycz MA, Field SK. Rofiumilast: flrst phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther. 2010;4:147-158.
41. Rabe KF, Bateman ED, O'Donnell DE, et al. Rofiumilast an oral anti-infiammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366:563-571.
42. Antoniu SA. New therapeutic options in the management of COPD focus on rofiumilast. Int J COPD. 2011;6:147-155.
43. Arcapta Neohaler [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; July 2011.
44. Novartis. Basel, Switzerland. Media release Novartis receives FDA approval for Arcapta Neohaler, a novel once-daily bronchodilator for chronic obstructive pulmonary disease. July, 2011. Available at: http://www.novartis.com/newsroom/mediareleases/en/2011/1528013.shtml. Accessed August 11, 2011.
45. Balint B, Watz H, Amos C, et al. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterolfiuticasone. Int J Chron Obstruct Pulmon Dis. 2010;5:311-318.
46. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008;155:291-299.
47. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.
48. Kornmann O, Dahl R, Centanni S, et al; for the INLIGHT-2 (Indacaterol Efflcacy Evaluation Using 150g Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37:273-279.
49. European Medicines Agency. European Public Assessment Report (EPAR) for Onbrez Breezhaler (indacaterol). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Summary_for_the_public/human/001114/WC500053733.pdf. Accessed August 12, 2011.
50. Karimi-Shah B. Indacaterol maleate (Arcapta Neohaler) for the long-term, once-daily, maintenance treatment of airfiow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. FDA Safety Addendum to Clinical Review [NDA 22-383]. Updated March 8, 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PulmonaryAllergyDrugsAdvisoryCommittee/UCM245638.pdf. Accessed August 12, 2011.
51. Cazzola M, Calzetta L, Matera MG. β(2)-adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011;163:4-17.
52. US National Institutes of Health. Vilanterol trifenatate. http://clinicaltrials.gov/ct2/results?term=vilanterol+trifenatate. Accessed August 12, 2011.
53. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J. 2009;34:757-769.
54. Vogelmeier C, Verkindre C, Cheung D, et al. Safety and tolerability of NVA237, a oncedaily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010;23:438-444.
55. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological proflle. J Pharmacol Exp Ther. 2009;331:740-751.
56. Jones PW, Rennard SI, Agusti A, et al. Efflcacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011;12:55.
57. Chanez P, Burge PS, Dahl D, et al. Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2010;23:15-21.
58. Aclidinium bromide. DPI Almirall: Genuair. Almirall Sofotec, Höhe, Germany. 2010. Available at: http://www.almirallsofotec.com/en/genuair_eklira.html. Accessed August 12, 2011.